Medical Policy
Cochlear Implant

Table of Contents
• Policy: Commercial
• Authorization Information
• Coding Information
• Description
• Policy History
• Information Pertaining to All Policies
• References
• Endnote

Policy Number: 478
BCBSA Reference Number: 7.01.05 (For Plan internal use only)

Related Policies
• Auditory Brainstem Implant, #481
• Implantable Bone-Conduction and Bone-Anchored Hearing Aids, #479
• Semi-Implantable and Fully Implantable Middle Ear Hearing Aid, #480
• Treatment of Tinnitus, #267

Policy¹
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Cochlear implantation of a U.S. Food and Drug Administration (FDA) – approved cochlear implant device may be MEDICALLY NECESSARY in individual age 9 months and older when criteria 1-3 are met:

  1. Individual has been diagnosed with one of the following:
         a. Bilateral hearing loss - defined as behavioral audimetric recorded word/sentence testing score (e.g. consonant-nucleus-consonant CNC) of ≤ 60% in the best aided binaural condition or Auditory Brainstem Response (ABR) hearing thresholds ≥ 70 dB (decibels) hearing level at frequencies 1000, 2000, and 4000 Hz (Hertz) who have shown limited or no benefit from hearing aids, OR

         b. Unilateral Hearing Loss (UHL) – includes Single Sided Deafness (SSD)
             i. Absence of usable hearing in one ear (recorded word/sentence testing score ≤ 40% or ABR thresholds ≥ 70dB at frequencies 1000, 2000, and 4000 Hz); AND
             ii. Normal to near-normal hearing in the contralateral ear (of note: hearing aid trial is not required if patient meets the above criteria), OR

         c. Asymmetric Hearing Loss (AHL)
             i. Absence of usable hearing in one ear (recorded word/sentence testing score ≤ 40% or ABR thresholds ≥ 70dB at frequencies 1000, 2000, and
4000 Hz). (Of note: hearing aid trial is not required if patient meets this criteria); **AND**

ii. Sensorineural hearing loss in the other ear that is usable (recorded word/sentence testing score > 60% or ABR thresholds < 70dB at frequencies 1000, 2000, and 4000 Hz).

2. Inner ear anatomy is expected to support cochlear implantation, **AND**

3. None of the following contraindications are present:
   a. Absent cochlea or known absent cochlear nerve (e.g., post trauma or postsurgical)
   b. Major cochlear ossification (defined as obliteration of both scala tympani and scala vestibuli in two or more turns of the cochlea)
   c. Otologic conditions that contraindicate surgery, such as:
      i. Active middle ear or mastoid infection
      ii. Tympanic membrane perforation
   d. Evidence of retrocochlear pathology (brainstem lesions involving cochlear nucleus, severe central auditory processing disorder)

Cochlear implantation as not otherwise meeting above criteria is **INVESTIGATIONAL**.

Upgrades of an existing, functioning external system to achieve aesthetic improvement, such as smaller profile components or a switch from a body-worn, external sound processor to a behind-the-ear model, are **INVESTIGATIONAL**.

Replacement of internal and/or external components solely for the purpose of upgrading to a system with advanced technology or to a next-generation device is considered **NOT MEDICALLY NECESSARY**.

Providers should determine the reasonable useful lifetime of the device to be five years—see **DME Payment Policy**.

Replacement of internal and/or external components is considered **MEDICALLY NECESSARY** only in a small subset of members who have inadequate response to existing component(s) to the point of interfering with the individual’s activities of daily living, or the component(s) is/are no longer functional and cannot be repaired. Copies of original medical records must be submitted either hard copy or electronically to support medical necessity.

Cochlear implantation with a hybrid cochlear implant/hearing aid device that includes the hearing aid integrated into the external sound processor of the cochlear implant (e.g., the Nucleus® Hybrid™ L24 Cochlear Implant System) may be considered **MEDICALLY NECESSARY** for individuals ages 18 years and older who meet all of the following criteria:

- Bilateral severe-to-profound high-frequency sensorineural hearing loss with residual low-frequency hearing sensitivity; **AND**
- Receive limited benefit from appropriately fitted bilateral hearing aids; **AND**
- Have the following hearing thresholds:
  - Low-frequency hearing thresholds ≤ 60 dB at frequencies 125, 250, and 500 Hz in the ear selected for implantation; **AND**
  - Severe to profound mid- to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz ≥75 dB hearing level) in the ear to be implanted; **AND**
  - Moderately severe to profound mid- to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz ≥ 60 dB hearing level) in the contralateral ear; **AND**
  - Recorded word/sentence testing score from 10% to 60% in the ear to be implanted in the preoperative aided condition and in the contralateral ear will be equal to or better than that of the ear to be implanted, but not more than 80% correct.
Prior Authorization Information

Inpatient
- For services described in this policy, precertification/preauthorization IS REQUIRED for all products if the procedure is performed inpatient.

Outpatient
- For services described in this policy, see below for products where prior authorization might be required if the procedure is performed outpatient.

<table>
<thead>
<tr>
<th>Product</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial Managed Care (HMO and POS)</td>
<td>Prior authorization is not required.</td>
</tr>
<tr>
<td>Commercial PPO and Indemnity</td>
<td>Prior authorization is not required.</td>
</tr>
</tbody>
</table>

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:

### CPT Codes:

<table>
<thead>
<tr>
<th>CPT codes</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>69930</td>
<td>Cochlear device implantation, with or without mastoidectomy</td>
</tr>
</tbody>
</table>

### HCPCS Codes

<table>
<thead>
<tr>
<th>HCPCS codes</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>L8614</td>
<td>Cochlear device; includes all internal and external components</td>
</tr>
<tr>
<td>L8615</td>
<td>Headset/headpiece for use with cochlear implant device, replacement</td>
</tr>
<tr>
<td>L8616</td>
<td>Microphone for use with cochlear implant device, replacement</td>
</tr>
<tr>
<td>L8617</td>
<td>Transmitting coil for use with cochlear implant device, replacement</td>
</tr>
<tr>
<td>L8618</td>
<td>Transmitter cable for use with cochlear implant device or auditory osseointegrated device, replacement</td>
</tr>
<tr>
<td>L8619</td>
<td>Cochlear implant, external speech processor and controller, integrated system, replacement</td>
</tr>
<tr>
<td>L8627</td>
<td>Cochlear implant, external speech processor, component, replacement</td>
</tr>
<tr>
<td>L8628</td>
<td>Cochlear implant, external controller component, replacement</td>
</tr>
<tr>
<td>L8629</td>
<td>Transmitting coil and cable, integrated, for use with cochlear implant device, replacement</td>
</tr>
</tbody>
</table>

The following ICD Diagnosis Codes are considered medically necessary when submitted with the CPT and HCPCS codes above if medical necessity criteria are met:

### ICD-10 Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis codes</th>
<th>Code Description</th>
</tr>
</thead>
</table>
Description
The basic structure of a cochlear implant includes both external and internal components. The external components include a microphone, an external sound processor, and an external transmitter. The internal components are implanted surgically and include an internal receiver implanted within the temporal bone and an electrode array that extends from the receiver into the cochlea through a surgically created opening in the round window of the middle ear.

Sounds picked up by the microphone are carried to the external sound processor, which transforms sound into coded signals that are then transmitted transcutaneously to the implanted internal receiver. The receiver converts the incoming signals into electrical impulses that are then conveyed to the electrode array, ultimately resulting in stimulation of the auditory nerve.

Summary
Description
A cochlear implant is a device for treatment of severe-to-profound hearing loss in individuals who only receive limited benefit from amplification with hearing aids. A cochlear implant provides direct electrical stimulation to the auditory nerve, bypassing the usual transducer cells that are absent or nonfunctional in deaf cochlea.

Summary of Evidence
For individuals who have bilateral sensorineural hearing loss who receive the cochlear implant(s), the evidence includes randomized controlled trials (RCTs) and multiple systematic reviews and technology assessments. Relevant outcomes are symptoms, functional outcomes, and treatment-related mortality and morbidity. The available studies have reported improvements in speech reception and quality of life measures. Although the available RCTs and other studies measured heterogeneous outcomes and included varying patient populations, the findings are consistent across multiple studies and settings. In addition to consistent improvement in speech reception (especially in noise), studies showed improvements in sound localization with bilateral devices. Studies have also suggested that earlier implantation may be preferred. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have unilateral sensorineural hearing loss who receive the cochlear implant(s), the evidence includes small open-label RCTs, a feasibility study, prospective and retrospective studies reporting within-subjects comparisons, and systematic reviews of observational studies. Relevant outcomes are symptoms, functional outcomes, and treatment-related mortality and morbidity. Given the natural history of hearing loss, pre- and postimplantation comparisons may be appropriate for objectively measured outcomes. However, the available evidence for the use of cochlear implants in improving outcomes for patients with unilateral hearing loss, with or without tinnitus, is limited by small sample sizes and heterogeneity in evaluation protocols and outcome measurements. A small feasibility study in adults with single-sided deafness or asymmetric hearing loss demonstrated improvements in sound perception, sound localization, and subjective measures of quality of life compared to baseline conditions. Inconsistent sound localization and binaural hearing outcomes have been reported in 2 small RCTs. Prospective studies assessing outcomes compared to best-aided hearing controls beyond 6 months are lacking. Ongoing postmarketing in adults and children may further elucidate outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have a high-frequency sensorineural hearing loss with preserved low-frequency hearing who receive a hybrid cochlear implant that includes a hearing aid integrated into the external sound
processor of the cochlear implant, the evidence includes prospective and retrospective studies using single-arm, within-subject comparisons pre- and postintervention and systematic reviews. Relevant outcomes are symptoms, functional outcomes, and treatment-related mortality and morbidity. The available evidence has suggested that a hybrid cochlear implant system is associated with improvements in hearing of speech in quiet and noise. The available evidence has also suggested that a hybrid cochlear implant improves speech recognition better than a hearing aid alone. Some studies have suggested that a shorter cochlear implant insertion depth may be associated with preserved residual low-frequency hearing, although there is uncertainty about the potential need for reoperation after hybrid cochlear implantation if there is a loss of residual hearing. Studies reporting on long-term outcomes and results of reimplantation are lacking. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Policy History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>4/2023</td>
<td>Annual policy review. Minor editorial refinements to policy statements; intent unchanged.</td>
</tr>
<tr>
<td>3/2022</td>
<td>Annual policy review. Description, summary, and references updated. Policy statements unchanged.</td>
</tr>
<tr>
<td>1/2022</td>
<td>Clarified coding information</td>
</tr>
<tr>
<td>5/2021</td>
<td>Policy statement on replacement of internal and/or external components solely for the purpose of upgrading to a next-generation device clarified; providers should determine the reasonable useful lifetime of the device to be five years.</td>
</tr>
<tr>
<td>1/2021</td>
<td>Medicare information removed. See MP #132 Medicare Advantage Management for local coverage determination and national coverage determination reference.</td>
</tr>
<tr>
<td>1/2018</td>
<td>Clarified coding information</td>
</tr>
<tr>
<td>12/2016</td>
<td>Annual policy review. Policy statement changed to indicate that cochlear implantation with a hybrid cochlear implant/hearing aid system is considered medically necessary for patients meeting criteria. References added. Effective 12/1/2016.</td>
</tr>
<tr>
<td>7/2015</td>
<td>Annual policy review. New references added.</td>
</tr>
<tr>
<td>12/2014</td>
<td>Correction made to last line of the Summary.</td>
</tr>
<tr>
<td>10/2014</td>
<td>Annual policy review. New references added.</td>
</tr>
<tr>
<td>7/2014</td>
<td>Updated Coding section with ICD10 procedure and diagnosis codes, effective 10/2015.</td>
</tr>
<tr>
<td>1/2014</td>
<td>Coding information clarified. Updated to add new CPT codes 92521-92524.</td>
</tr>
<tr>
<td>12/2013</td>
<td>Annual policy review. New investigational indications described. Coding information clarified.</td>
</tr>
<tr>
<td>5/2013</td>
<td>Annual policy review. New references added.</td>
</tr>
<tr>
<td>Date</td>
<td>Event Description</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>7/2007</td>
<td>Annual policy review. No changes to policy statements.</td>
</tr>
</tbody>
</table>

**Information Pertaining to All Blue Cross Blue Shield Medical Policies**
Click on any of the following terms to access the relevant information:
- Medical Policy Terms of Use
- Managed Care Guidelines
- Indemnity/PPO Guidelines
- Clinical Exception Process
- Medical Technology Assessment Guidelines

**References**


Additional References


Endnotes

1 Based on expert opinion